Review



proliferation medium  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 98

    Structured Review

    PromoCell proliferation medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Proliferation Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 479 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proliferation medium/product/PromoCell
    Average 98 stars, based on 479 article reviews
    proliferation medium - by Bioz Stars, 2026-05
    98/100 stars

    Images

    1) Product Images from "Increased utrophin expression in healthy and DMD patient derived myoblasts in response to ERK1/2 and EZH2 inhibitor treatment"

    Article Title: Increased utrophin expression in healthy and DMD patient derived myoblasts in response to ERK1/2 and EZH2 inhibitor treatment

    Journal: bioRxiv

    doi: 10.64898/2026.04.13.718206

    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Figure Legend Snippet: Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.

    Techniques Used: Derivative Assay, Staining, Concentration Assay, Cell Culture, Cell Characterization, Control, Quantitative RT-PCR, Comparison



    Similar Products

    98
    PromoCell proliferation medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Proliferation Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proliferation medium/product/PromoCell
    Average 98 stars, based on 1 article reviews
    proliferation medium - by Bioz Stars, 2026-05
    98/100 stars
      Buy from Supplier

    99
    Beijing Solarbio Science proliferation medium
    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in <t>proliferation</t> media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.
    Proliferation Medium, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proliferation medium/product/Beijing Solarbio Science
    Average 99 stars, based on 1 article reviews
    proliferation medium - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    86
    Fisher Scientific proliferation medium
    On day 5 of culture in differentiation medium, the hydrogels were fixed, sectioned at 10 µm and stained for (a) Ki-67 and (b) Ki-67 with Hoescht to confirm the presence of proliferative cells. Scale bars are 100 µm. (c) These images were analyzed using cell profiler to determine the percentage of nuclear expression (* p < 0.05, N = 11, error bars represent ± SEM). A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance difference between the groups. The small sphere, low density group had a higher proportion of nuclear Ki-67 expression than the small sphere, high density group. (d) Flow cytometry was performed to compare <t>proliferation,</t> represented by the percentage of EdU positive cells. A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance between the groups. ( N = 3–4, error bars represent ± SEM). No significant differences were observed.
    Proliferation Medium, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proliferation medium/product/Fisher Scientific
    Average 86 stars, based on 1 article reviews
    proliferation medium - by Bioz Stars, 2026-05
    86/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology proliferation medium
    On day 5 of culture in differentiation medium, the hydrogels were fixed, sectioned at 10 µm and stained for (a) Ki-67 and (b) Ki-67 with Hoescht to confirm the presence of proliferative cells. Scale bars are 100 µm. (c) These images were analyzed using cell profiler to determine the percentage of nuclear expression (* p < 0.05, N = 11, error bars represent ± SEM). A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance difference between the groups. The small sphere, low density group had a higher proportion of nuclear Ki-67 expression than the small sphere, high density group. (d) Flow cytometry was performed to compare <t>proliferation,</t> represented by the percentage of EdU positive cells. A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance between the groups. ( N = 3–4, error bars represent ± SEM). No significant differences were observed.
    Proliferation Medium, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proliferation medium/product/Elabscience Biotechnology
    Average 93 stars, based on 1 article reviews
    proliferation medium - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    96
    PromoCell proliferation media
    On day 5 of culture in differentiation medium, the hydrogels were fixed, sectioned at 10 µm and stained for (a) Ki-67 and (b) Ki-67 with Hoescht to confirm the presence of proliferative cells. Scale bars are 100 µm. (c) These images were analyzed using cell profiler to determine the percentage of nuclear expression (* p < 0.05, N = 11, error bars represent ± SEM). A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance difference between the groups. The small sphere, low density group had a higher proportion of nuclear Ki-67 expression than the small sphere, high density group. (d) Flow cytometry was performed to compare <t>proliferation,</t> represented by the percentage of EdU positive cells. A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance between the groups. ( N = 3–4, error bars represent ± SEM). No significant differences were observed.
    Proliferation Media, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proliferation media/product/PromoCell
    Average 96 stars, based on 1 article reviews
    proliferation media - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    96
    PromoCell dedicated proliferation medium
    On day 5 of culture in differentiation medium, the hydrogels were fixed, sectioned at 10 µm and stained for (a) Ki-67 and (b) Ki-67 with Hoescht to confirm the presence of proliferative cells. Scale bars are 100 µm. (c) These images were analyzed using cell profiler to determine the percentage of nuclear expression (* p < 0.05, N = 11, error bars represent ± SEM). A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance difference between the groups. The small sphere, low density group had a higher proportion of nuclear Ki-67 expression than the small sphere, high density group. (d) Flow cytometry was performed to compare <t>proliferation,</t> represented by the percentage of EdU positive cells. A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance between the groups. ( N = 3–4, error bars represent ± SEM). No significant differences were observed.
    Dedicated Proliferation Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/dedicated proliferation medium/product/PromoCell
    Average 96 stars, based on 1 article reviews
    dedicated proliferation medium - by Bioz Stars, 2026-05
    96/100 stars
      Buy from Supplier

    99
    Beijing Solarbio Science nsc proliferation medium
    Preparation and bioactivity evaluation of immobilized recombinant growth factors and the construction of the neuroregenerative coating fiber network scaffold. (A) SDS-PAGE gel showed the preparation process of immobilized recombinant growth factors D-IGF1 and D-NGF including: marker (M), pre-induction (1), post-induction (2), supernatant after centrifugation (3), pellet after centrifugation (4), refolded protein solution (5), flow-through liquid (6), wash liquid (7), elution liquid (8). (B) The effect of different densities of D-IGF1 and D-NGF on <t>NSC</t> <t>proliferation.</t> (C–D) The effect of different densities of D-IGF1 and D-NGF on neural stem cell differentiation. Scale bars, 100 μm (E) SEM images of the surface morphology of fiber scaffolds prepared under different process parameters. Scale bars, 10 μm (F–G) Biocompatibility testing of the scaffold. (H) Contact angle analysis. (I) FT-IR analysis. (J) XPS analysis. (Data are shown as the mean ± SD, n = 3, ∗p < 0.05,∗∗p < 0.01).
    Nsc Proliferation Medium, supplied by Beijing Solarbio Science, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/nsc proliferation medium/product/Beijing Solarbio Science
    Average 99 stars, based on 1 article reviews
    nsc proliferation medium - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    99
    Thermo Fisher proliferation medium
    Preparation and bioactivity evaluation of immobilized recombinant growth factors and the construction of the neuroregenerative coating fiber network scaffold. (A) SDS-PAGE gel showed the preparation process of immobilized recombinant growth factors D-IGF1 and D-NGF including: marker (M), pre-induction (1), post-induction (2), supernatant after centrifugation (3), pellet after centrifugation (4), refolded protein solution (5), flow-through liquid (6), wash liquid (7), elution liquid (8). (B) The effect of different densities of D-IGF1 and D-NGF on <t>NSC</t> <t>proliferation.</t> (C–D) The effect of different densities of D-IGF1 and D-NGF on neural stem cell differentiation. Scale bars, 100 μm (E) SEM images of the surface morphology of fiber scaffolds prepared under different process parameters. Scale bars, 10 μm (F–G) Biocompatibility testing of the scaffold. (H) Contact angle analysis. (I) FT-IR analysis. (J) XPS analysis. (Data are shown as the mean ± SD, n = 3, ∗p < 0.05,∗∗p < 0.01).
    Proliferation Medium, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/proliferation medium/product/Thermo Fisher
    Average 99 stars, based on 1 article reviews
    proliferation medium - by Bioz Stars, 2026-05
    99/100 stars
      Buy from Supplier

    Image Search Results


    Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.

    Journal: bioRxiv

    Article Title: Increased utrophin expression in healthy and DMD patient derived myoblasts in response to ERK1/2 and EZH2 inhibitor treatment

    doi: 10.64898/2026.04.13.718206

    Figure Lengend Snippet: Corresponding to . a . Basal levels of MYOD1 mRNA in primary healthy human myoblasts (n=6) and primary DMD patient-derived myoblasts (n=16). Lines show median and quartiles. b . AB1098 cells were treated with 10 μM LY32 +/- 10 μM GSK503 or vehicle (DMSO) for 24 hours. Directly following treatment (0 days since drug removal) cells were manually counted, with trypan blue staining to discount dead cells. Cells were then replated at a constant concentration, cultured in proliferation media without drugs for 24 hours and counted again (1 day since drug removal). Cells were then replated at a constant concentration and cultured again for 6 days before counting (7 days since drug removal). Cells were passaged once in this 6-day period. Cell count is shown relative to the vehicle only control for each time point. c . RT-qPCR of MYOD1 in immortalised myoblasts AB1190 and AB1098 following treatment with varying concentrations of Ruxolitinib (Ruxo). Results are shown relative to vehicle treated sample with a two-way ANOVA with Dunnetts multiple comparison test to determine significance. Graph shows mean (n=3) +/- SEM. a-b . MYOD1 is normalised against TBP . *p<0.05, ***p<0.001, ****p<0.0001.

    Article Snippet: The muscle biopsy was enzymatically digested in basal medium (C-23060; PromoCell, Heidelberg, Germany) containing collagenase D (2 mg/mL, Roche, Germany) and Dispase II (2 mg/mL, Sigma) for 1 h at 37°C with trituration every 15 min. After filtering through a 100-μm filter (BD Falcon) and centrifugation cells were resuspended in proliferation medium (15% FBS, C-23060; PromoCell, Heidelberg, Germany) and transferred to a T-25 tissue culture vessel (Nunc, Germany).

    Techniques: Derivative Assay, Staining, Concentration Assay, Cell Culture, Cell Characterization, Control, Quantitative RT-PCR, Comparison

    On day 5 of culture in differentiation medium, the hydrogels were fixed, sectioned at 10 µm and stained for (a) Ki-67 and (b) Ki-67 with Hoescht to confirm the presence of proliferative cells. Scale bars are 100 µm. (c) These images were analyzed using cell profiler to determine the percentage of nuclear expression (* p < 0.05, N = 11, error bars represent ± SEM). A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance difference between the groups. The small sphere, low density group had a higher proportion of nuclear Ki-67 expression than the small sphere, high density group. (d) Flow cytometry was performed to compare proliferation, represented by the percentage of EdU positive cells. A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance between the groups. ( N = 3–4, error bars represent ± SEM). No significant differences were observed.

    Journal: Journal of Materials Chemistry. B

    Article Title: Systematic investigation of the effects of neural stem cell spheroid size and density on fate specification in 3D culture

    doi: 10.1039/d5tb01589h

    Figure Lengend Snippet: On day 5 of culture in differentiation medium, the hydrogels were fixed, sectioned at 10 µm and stained for (a) Ki-67 and (b) Ki-67 with Hoescht to confirm the presence of proliferative cells. Scale bars are 100 µm. (c) These images were analyzed using cell profiler to determine the percentage of nuclear expression (* p < 0.05, N = 11, error bars represent ± SEM). A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance difference between the groups. The small sphere, low density group had a higher proportion of nuclear Ki-67 expression than the small sphere, high density group. (d) Flow cytometry was performed to compare proliferation, represented by the percentage of EdU positive cells. A test of normality (Shapiro–Wilk test) and subsequently ordinary two-way ANOVA (Tukey's multiple comparison test) was performed using GraphPad Prism to determine significance between the groups. ( N = 3–4, error bars represent ± SEM). No significant differences were observed.

    Article Snippet: They were then cultured in these plates with proliferation medium (0.02 μg mL −1 epidermal growth factor (Fisher Scientific, AF10015100), 0.02 μg mL −1 basic fibroblast growth factor (ThermoFisher Scientific, 100-18B-100UG), 2 μg mL −1 heparin (Millipore Sigma, H6279-25KU) and 0.2× ABAM (Millipore Sigma, A5955-20 mL) in basal medium (Millipore Sigma, SCM003)) for 48 hours in an incubator (37 °C, 5% CO 2 ).

    Techniques: Staining, Expressing, Comparison, Flow Cytometry

    Preparation and bioactivity evaluation of immobilized recombinant growth factors and the construction of the neuroregenerative coating fiber network scaffold. (A) SDS-PAGE gel showed the preparation process of immobilized recombinant growth factors D-IGF1 and D-NGF including: marker (M), pre-induction (1), post-induction (2), supernatant after centrifugation (3), pellet after centrifugation (4), refolded protein solution (5), flow-through liquid (6), wash liquid (7), elution liquid (8). (B) The effect of different densities of D-IGF1 and D-NGF on NSC proliferation. (C–D) The effect of different densities of D-IGF1 and D-NGF on neural stem cell differentiation. Scale bars, 100 μm (E) SEM images of the surface morphology of fiber scaffolds prepared under different process parameters. Scale bars, 10 μm (F–G) Biocompatibility testing of the scaffold. (H) Contact angle analysis. (I) FT-IR analysis. (J) XPS analysis. (Data are shown as the mean ± SD, n = 3, ∗p < 0.05,∗∗p < 0.01).

    Journal: Materials Today Bio

    Article Title: Neuroactive network tissue based on dual-factor neuroregenerative bioactive coating scaffolds and neural stem cells for spinal cord injury repair

    doi: 10.1016/j.mtbio.2025.102172

    Figure Lengend Snippet: Preparation and bioactivity evaluation of immobilized recombinant growth factors and the construction of the neuroregenerative coating fiber network scaffold. (A) SDS-PAGE gel showed the preparation process of immobilized recombinant growth factors D-IGF1 and D-NGF including: marker (M), pre-induction (1), post-induction (2), supernatant after centrifugation (3), pellet after centrifugation (4), refolded protein solution (5), flow-through liquid (6), wash liquid (7), elution liquid (8). (B) The effect of different densities of D-IGF1 and D-NGF on NSC proliferation. (C–D) The effect of different densities of D-IGF1 and D-NGF on neural stem cell differentiation. Scale bars, 100 μm (E) SEM images of the surface morphology of fiber scaffolds prepared under different process parameters. Scale bars, 10 μm (F–G) Biocompatibility testing of the scaffold. (H) Contact angle analysis. (I) FT-IR analysis. (J) XPS analysis. (Data are shown as the mean ± SD, n = 3, ∗p < 0.05,∗∗p < 0.01).

    Article Snippet: The resulting cells were resuspended in NSC proliferation medium containing DMEM/F12 (Gibco, A4192001, USA), 1 % penicillin-streptomycin (PS, Sigma-Aldrich, USA), 1 % glutamine (Gibco, USA), 20 ng mL −1 basic fibroblast growth factor (bFGF, Solarbio, China), and 20 ng mL −1 epidermal growth factor (EGF, Solarbio, China).

    Techniques: Recombinant, SDS Page, Marker, Centrifugation, Cell Differentiation